Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Carl E. Allen, Olive Eckstein, Paul M. Williams, Sinchita Roy-Chowdhuri, David R Patton, Brent Coffey, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd Allen Alonzo, Stacey L. Berg, Alok Jaju, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James V. Tricoli, Katherine A. Janeway, Nita Seibel, Donald Williams Parsons
Institutions: Baylor College of Medicine, Frederick National Laboratory for Cancer Research, The University of Texas MD Anderson Cancer Center, National Cancer Institute, Mayo Clinic, Children's Oncology Group, University of Southern California, Lurie Children's Hospital, Children's Hospital of Philadelphia, Seattle Children's Hospital, University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3166776131